SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-22-007374
Filing Date
2022-05-04
Accepted
2022-05-04 16:04:42
Documents
69
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q apls-20220331.htm   iXBRL 10-Q 2099605
2 EX-31.1 apls-ex31_1.htm EX-31.1 21116
3 EX-31.2 apls-ex31_2.htm EX-31.2 20312
4 EX-32.1 apls-ex32_1.htm EX-32.1 11365
5 EX-32.2 apls-ex32_2.htm EX-32.2 11518
  Complete submission text file 0000950170-22-007374.txt   7806520

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT apls-20220331_pre.xml EX-101.PRE 314607
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT apls-20220331_def.xml EX-101.DEF 188531
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT apls-20220331_lab.xml EX-101.LAB 441588
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT apls-20220331_cal.xml EX-101.CAL 51109
10 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT apls-20220331.xsd EX-101.SCH 60514
63 EXTRACTED XBRL INSTANCE DOCUMENT apls-20220331_htm.xml XML 1353897
Mailing Address 100 FIFTH AVENUE WALTHAM MA 02451
Business Address 100 FIFTH AVENUE WALTHAM MA 02451 617-977-5700
Apellis Pharmaceuticals, Inc. (Filer) CIK: 0001492422 (see all company filings)

IRS No.: 271537290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38276 | Film No.: 22891465
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences